Get the Stockscreener App
0.4801
3.81%
-0.019
Redhill Biopharma Ltd Adr stock is traded at $0.4801, with a volume of 84,784.
It is down -3.81% in the last 24 hours and down -12.71% over the past month.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
See More
Previous Close:
$0.4991
Open:
$0.500001
24h Volume:
84,784
Relative Volume:
0.05
Market Cap:
$4.27M
Revenue:
$35.52M
Net Income/Loss:
$11.39M
P/E Ratio:
-0.2071
EPS:
-2.3181
Net Cash Flow:
$-26.04M
1W Performance:
-10.93%
1M Performance:
-12.71%
6M Performance:
-38.80%
1Y Performance:
-69.42%
1-Day Range:
$0.48
$0.5199
1-Week Range:
$0.48
$0.56
52-Week Range:
$0.4351
$2.14
Redhill Biopharma Ltd Adr Stock (RDHL) Company Profile
Compare RDHL vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RDHL
Redhill Biopharma Ltd Adr
|
0.4801 | 4.27M | 35.52M | 11.39M | -26.04M | -2.3181 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Redhill Biopharma Ltd Adr Stock (RDHL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-31-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-11-20 | Initiated | BTIG Research | Buy |
| Jul-12-19 | Upgrade | WBB Securities | Buy → Strong Buy |
| Mar-12-19 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Jan-26-18 | Initiated | Nomura | Buy |
| Oct-06-17 | Initiated | Seaport Global Securities | Buy |
| Oct-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-17 | Reiterated | FBR & Co. | Outperform |
| Jul-27-16 | Reiterated | FBR Capital | Outperform |
| Sep-29-15 | Initiated | Nomura | Buy |
| Jul-29-15 | Reiterated | ROTH Capital | Buy |
| Jun-17-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-15 | Reiterated | ROTH Capital | Buy |
View All
Redhill Biopharma Ltd Adr Stock (RDHL) Latest News
Nasdaq gives RedHill Biopharma (NASDAQ: RDHL) more time to clear its $1 bid-price hurdle - Stock Titan
Form 4 RedHill Biopharma Ltd. For: 6 October By Investing.com - Investing.com Canada
Form 4 RedHill Biopharma Ltd. For: 6 October By Investing.com - Investing.com UK
RedHill Biopharma closes $19.4M private placement - scanx.trade
Redhill Biopharma Ltd (NASDAQ: RDHL) Share Price, RDHL Stock News, RDHL Share Price & Updates - Kalkine
RedHill Biopharma Ltd. (RDHL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Small Caps Test Their 200-Day Line as Yields Grind Higher and Earnings Season Stirs - GlobeNewswire
RedHill Biopharma Reshapes GI Portfolio With Rebyota, Clenpiq Deal and Talicia Sale - The Globe and Mail
A 70% Talicia stake sale brings RedHill Biopharma (RDHL) cash plus potential sales milestone payments. - Stock Titan
Continuing-operations revenue fell to zero at RedHill Biopharma (RDHL), while its first-half loss widened. - Stock Titan
RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results - PR Newswire
One dose showed over 70% success preventing repeat infections from C. diff bacteria. RedHill acquired its rights. - Stock Titan
RedHill Biopharma stock jumps 95% after $18M Talicia divestment - scanx.trade
RDHL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
RedHill Biopharma Buys Global Rights to Two Established GI Drugs from Ferring - BioBuzz
RedHill Biopharma Buys Global Rights to Two Established GI Drugs from Ferring - BioBuzz
RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties? - Yahoo Finance
Redhill Biopharma Ltd.ADR Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
RedHill acquires rights to two GI drugs from Ferring for $12M - Investing.com Nigeria
RedHill acquires rights to two GI drugs from Ferring for $12M - Investing.com Australia
RedHill acquires rights to two GI drugs from Ferring for $12M - Investing.com India
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq® - Barchart.com
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq® - PR Newswire
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq® - Stock Titan
Redhill Biopharma Ltd.ADR Key Financial Ratios – Valuation, Profitability & More - Value Research
Redhill Biopharma Ltd. stock Analysis: Overbought Signals and Key Levels to Watch - The Cryptonomist
RedHill Biopharma Sells Talicia to Apotex for $18M Upfront Plus $35M in Potential Milestones - kalkinemedia.com
RedHill Biopharma (RDHL) sells Talicia stake for upfront pay, milestone upside - Stock Titan
Redhill Biopharma Stock Doubles In One Session — Here's Why - Yahoo Finance
RedHill Biopharma jumps on $18 million Talicia sale to Apotex - Quiver Quantitative
RedHill Biopharma (NASDAQ: RDHL) Soars to $1.60Monetizes Talicia Stake in $18 Million Cash Deal With Apotex - Investorideas.com
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities - PR Newswire
RedHill Biopharma jumps on $18 million Talicia sale to Apotex - Quiver Quantitative
RDHL Stock Volatility Draws Trader Focus As Biotech Reprices - StocksToTrade
RDHL Stock Draws Trader Focus As Volatility Spikes - StocksToTrade
Redhill Biopharma Ltd.ADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Can RedHill Biopharma (NASDAQ:RDHL) Show Commercial Progress Today? - Kalkine Media
RedHill Biopharma (RDHL) investors back all AGM resolutions in 2026 - Stock Titan
RedHill Biopharma (NASDAQ: RDHL) adjourns AGM after quorum shortfall - Stock Titan
Redhill Biopharma (RDHL) Advances 3.4% as Shares Test Key Resistance at $0.70MACD Signal Stocks - careplusvn.com
Redhill Biopharma (RDHL) Edges Higher: Penny Stock Approaches Key Resistance at $0.68Exhaustion Gap - careplusvn.com
Ebola Cases and Deaths Rapidly MountRedHill Updates on Opaganib Emergency Outbreak Development - Sahm
Redhill Biopharma (RDHL) Rises 4.29%: Testing Key Resistance at $0.77Social Sentiment - careplusvn.com
Redhill Biopharma Ltd. Revenue Breakdown – NASDAQ:RDHL - tradingview.com
RedHill Biopharma Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:RDHL) - TradingView
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement - Sahm
RedHill Biopharma closes $6 million private placement - Investing.com
RedHill Biopharma closes $6 million private placement By Investing.com - Investing.com South Africa
Form 6K Redhill Biopharma Ltd For: 22 June By Investing.com - Investing.com Nigeria
Redhill Biopharma Ltd Adr Stock (RDHL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Redhill Biopharma Ltd Adr Stock (RDHL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Raday Gilead | Chief Operating Officer |
Jul 10 '26 |
Sale |
0.00 |
14,130,000 |
1,413 |
218,780,000 |
| Raday Gilead | Chief Operating Officer |
Apr 06 '26 |
Sale |
0.00 |
15,740,000 |
1,574 |
261,060,000 |
1.08%
3.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):